Jan 9 (Reuters) - Clinical biopharmaceutical company

Eikon Therapeutics on Friday revealed wider nine-month losses in

its filing for ‌an initial public offering in the ​United States.

The company disclosed a ‍net loss attributable to ⁠common

stockholders of ⁠about $254 million for the nine months ‌ended

September 30, compared ​with a loss about $179 million a year

earlier.

IPOs are likely ⁠to gain ‍momentum ​in 2026 as anticipated

interest rate cuts bolster investor confidence and appetite ‍for

risk, encouraging late-stage drugmakers to test public markets

after the holiday season.

Earlier on Friday another biopharmaceutical company,

Veradermics, also filed ​for ‍a U.S. IPO.

Eikon Therapeutics will list on the Nasdaq ​under the symbol

"EIKN".

It is a late-stage clinical biopharmaceutical firm

developing innovative medicines for serious unmet medical needs,

with an initial focus on oncology.

J.P. Morgan, ​Morgan Stanley and BofA Securities are the

underwriters for the offering.